Literatur
- 1
Apperley J F, Schultheis B, Chase A. et al .
Chronic myeloproliferative diseases with
t(5;12) and a PDGFRb fusion gene: Complete cytogenetic remissions
on STI571.
Blood.
2001;
98
(Suppl 1)
726a
- 2
Barthe C, Cony-Makhoul P, Melo J V, Reiffers J, Mahon F X.
Roots of clinical
resistance to STI-571 cancer therapy.
Science.
2001;
293
2163a
- 3
Beham Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Hofler G, Haas O A, Linkesch W.
Treatment
of chronic myelogenous leukemia with the tyrosine kinase inhibitor
STI571 results in marked regression of bone marrow fibrosis.
Blood.
2002;
99
381-383
- 4
Brouard M, Saurat J H.
Cutaneous reactions
to STI571.
N Engl J Med.
2001;
345
618-619
- 5
Buchdunger E, Cioffi C L, Law N, Stover D, Ohno-Jones S, Druker B J, Lydon N B.
Abl
protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal
transduction mediated by c-kit and platelet-derived growth factor
receptors.
J Pharmacol Exp Ther.
2000;
295
139-145
- 6
Deininger M WN, Goldman J M, Lydon N, Melo J V.
The tyrosine
kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive
cells.
Blood.
1997;
90
3691-3698
- 7
Druker B J, Kantarjian H M, Talpaz M, Paquette R, Mauro M J, Rosamilia M, Zoellner U,
Resta D, Capdeville R, Sawyers C L.
A phase I study
of Gleevec (imatinib mesylate) administered concomitantly with cytosine
arabinoside (Ara-C) in patients with Philadelphia positive chronic
myeloid leukemia (CML).
Blood.
2001;
98
(Suppl 1)
845a-846a
- 8
Druker B J, Lydon N B.
Lessons learned
from the development of an Abl tyrosine kinase inhibitor for chronic
myelogenous leukemia.
J Clin Invest.
2000;
105
3-7
- 9
Druker B J, Sawyers C L, Kantarjian H, Resta D J, Fernandez Reese S, Ford J M, Capdeville R,
Talpaz M.
Activity of a specific
inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of
chronic myeloid leukemia and acute lymphoblastic leukemia with the
Philadelphia chromosome.
N Engl J Med.
2001;
344
1038-1042
- 10
Druker B J, Talpaz M, Resta D J, Peng B, Buchdunger E, Ford J M, Lydon N B, Kantarjian H,
Capdeville R, Ohno-Jones S, Sawyers C L.
Efficacy
and safety of a specific inhibitor of the BCR-ABL tyrosine kinase
in chronic myeloid leukemia.
N Engl J Med.
2001;
344
1031-1037
- 11
Druker B J, Tamura S, Buchdunger E, Ohno S, Segal G M, Fanning S, Zimmermann J, Lydon N B.
Effects of a
selective inhibitor of the Abl tyrosine kinase on the growth of
Bcr-Abl positive cells.
Nat Medic.
1996;
2
561-566
- 12
Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F,
Gianazza E, Brueggen J, Cozens R, Piotelli P, Pogliani E, Corneo G, Formelli F, D’Incalci M.
Role of α1
acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic
cells to the Abl inhibitor STI571.
J Natl Cancer Inst.
2000;
92
1641-1650
- 13
Gambacorti-Passerini C, le C outre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E,
Di Nicola M, Biondi A, Corneo G M, Belotti D, Pogliani E, Lydon N B.
Inhibition of
the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic
cells and induces apoptosis.
Blood Cells Mol Diseases.
1997;
23
380-394
- 14
Gorre M E, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P N, Sawyers C L.
Clinical resistance
to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Science.
2001;
293
876-880
- 15
Hehlmann R, Hochhaus A.
Evidenzbasierte Therapie
der chronischen myeloischen Leukämie.
Dtsch Ärztebl.
2001;
98
A1834-A1837
- 16
Heinrich M C, Griffith D J, Druker B J, Wait C L, Ott K A, Zigler A J.
Inhibition
of c-kit receptor tyrosine kinase activity by STI571, a selective
tyrosine kinase inhibitor.
Blood.
2000;
96
925-932
- 17
Hochhaus A, Kreil S, Corbin A, La
Rosée P, Lahaye T, Berger U, Cross N CP, Linkesch W, Druker B J, Hehlmann R.
Roots of clinical resistance
to STI-571 cancer therapy.
Science.
2001;
293
2163a
- 18
Joensuu H, Roberts P J, Sarlomo-Rikala M, Andersson L C, Tervahartiala P, Tuveson D,
Silberman S L, Capdeville R, Dimitrijevic S, Druker B, Demetri G D.
Effect
of the tyrosine kinase inhibitor STI571 in a patient with a metastatic
gastrointestinal stromal tumor.
N Engl J Med.
2001;
344
1052-1056
- 19
Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y.
In
vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination
with commonly used antileukemic agents.
Blood.
2001;
97
1999-2007
- 20
Kantarjian H M, Sawyers C L, Hochhaus A, Guilhot F, Schiffer C A, Deininger M W, Gambacorti-Passerini C,
Stone R M, Goldman J, Fischer T, Rosamilia M, Zoellner U, Resta D, Capdeville R, Druker B J.
GleevecTM
(Imatinib mesylate) induced hematologic and cytogenetic responses
confirmed and expanded in patients with chronic myeloid leukemia
(CML) - A phase II study update.
Blood.
2001;
98 (Suppl
1)
845a
- 21
Kilic T, Alberta J A, Zdunek P R, Acar M, Iannarelli P, O’Reilly T, Buchdunger E,
Black P M, Stiles C.
Intracranial inhibition
of platelet-derived growth factor-mediated glioblastoma cell growth
by an orally active kinase inhibitor of the 2-phenylaminopyrimidine
class.
Cancer Research.
2000;
60
5143-5150
- 22
Kreil S, Müller M C, Lahaye T, La Rosée P, Corbin A M, Schoch C, Cross N CP, Berger U,
Rieder H, Druker B J, Gschaidmeier H, Hehlmann R, Hochhaus A.
Molecular and chromosomal
mechanisms of resistance in CML patients after STI571 (Glivec) therapy.
Blood.
2001;
98
(Suppl1)
435a
- 23
Krystal G W, Honsawek S, Litz J, Buchdunger E.
The selective tyrosine
kinase inhibitor STI571 inhibits small cell lung cancer growth.
Clin
Cancer Res.
2000;
6
3319-3326
- 24
Mahon F X, Deininger M WN, Schultheis B, Chabrol J, Reiffers J, Golfdman J M, Melo J V.
Selection
and characterization of BCR-ABL positive cell lines with differential
sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms
of resistance.
Blood.
2000;
96
1070-1079
- 25
Merx K, Kreil S, Lahaye T, Müller M C, Paschka P, Schoch C, Weisser A, Kuhn C, Landmann T,
Gschaidmeier H, Berger U, Hehlmann R, Hochhaus A.
Early
reduction of BCR-ABL mRNA transcript levels predicts cytogenetic
response to STI571 in chronic phase CML patients.
Blood.
2001;
98
(Suppl 1)
846a-847a
- 26
O’Brien S, Vallance S E, Craddock C, Holyoake T L, Goldman J M. the UK PISCES Group
.
PEGIntron and STI571 combination
evaluation study (PISCES) in chronic phase chronic myeloid leukaemia.
Blood.
2001;
98
(Suppl 1)
846a
- 27
O’Dwyer M E, Mauro M J, Kuyl J M, Paquette R, Sawyers C L, Druker B J.
Preliminary
evaluation of the combination of imatinib mesylate (Glevec) in combination
with low dose interferon-alpha for the treatment of chronic phase
CML.
Blood.
2001;
98 (Suppl
1)
846a
- 28
Okuda K, Weisberg E, Gilliland D G, Griffin J D.
ARG
tyrosine kinase activity is inhibited by STI571.
Blood.
2001;
97
2440-2448
- 29
Ottmann O G, Sawyers C, Druker B, Goldman J, O’Brien S G, Reiffers J, Silver R T,
Tura S, Fischer T, Niederwieser D, Schiffer C, Baccarani M, Gratwohl A, Hochhaus A,
Reese S F, Capdeville R.
Phase
II study of STI571 in adult patients with Philadelphia chromosome
(Ph) positive acute leukaemias.
Hematol J.
2001;
2
(Suppl 1)
93
- 30
Rubin B P, Singer S, Tsao C, Duensing A, Lux M L, Ruiz R, Hibbard M K, Chen C J, Xiao S,
Tuveson D A, Demetri G D, Fletcher D M, Fletcher J A.
KIT activation
is a ubiquitous feature of gastrointestinal stromal tumors.
Cancer
Res.
2001;
61
8118-8121
- 31
Sawyers C L.
Cancer
treatment in the STI571 era: What will change?.
J Clin
Oncol.
2001;
19 (Suppl 1)
13s-16s
- 32
Sawyers C L, Hochhaus A, Feldman E, Goldman J M, Miller C, Ottmann O G, Schiffer C A,
Talpaz M, Guilhot F, Niederwieser D, Ben-Am M, Gathmann I, Ford J, Druker B J. on
behalf of the
International Gleevec Study Group .
Gleevec/Glivec
(Imatinib mesylate, STI-571) in patients with chronic myeloid leukemia
(CML) in myeloid blast crisis: Updated results of a phase II study.
Blood.
2001;
98
(Suppl 1)
845a
- 33
Silver R T, Woolf S H, Hehlmann R, Appelbaum F R, Anderson J, Bennett C, Goldman J M,
Guilhot F, Kantarjian H M, Lichtin A E, Talpaz M, Tura S.
An evidence-based analysis
of the effect of busulfan, hydroxyurea, interferon, and allogeneic
bone marrow transplantation in treating the chronic phase of chronic
myeloid leukemia: Developed for the American Society of Hematology.
Blood.
1999;
94
1517-1536
- 34
Talpaz M, Silver R T, Druker B, Paquette R, Goldman J M, G ambacorti-Passerini C,
Guilhot F, Schiffer C A, Reese S F, Kantarjian H M, Ford J M.
GleevecTM
(formerly STI571): An active drug in patients with PH+ chronic
myeloid leukemia in accelerated phase - updated results
of a phase II study.
Blood.
2001;
98
(Suppl 1)
845a
- 35
Thiesing J T, Ohno-Jones S, Kolibaba K S, Druker B J.
Efficacy of STI571,
an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic
agents against Bcr-Abl-positive cells.
Blood.
2000;
96
3195-3199
- 36
Topaly J, Zeller W, Fruehauf S.
Synergistic
activity of the new ABL-specific tyrosine kinase inhibitor STI571
and chemotherapeutic drugs on BCR-ABL-positivbe chronic myelogenous
leukemia cells.
Leukemia.
2001;
15
342-347
- 37
van Oosterom A T, Judson I, Verweij J, Stroobants S, di Paola E D, Dimitrijevic S,
Martens M, Webb A, Sciot R, van
Glabbeke M, Silberman S, Nielsen O S, for t he European Organisation for Research
and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Safety and
efficacy of imatinib (STI571) in metastatic gastrointestinal stromal
tumours: a phase I study.
Lancet.
2001;
358
1421-1423
- 38
Weisberg E, Griffin J D.
Mechanism
of resistence to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed
hematopoietic cell lines.
Blood.
2000;
95
3498-3505
Korrespondenz
Priv.-Doz. Dr. med. Andreas Hochhaus
III. Medizinische Universitätsklinik, Fakultät
für Klinische Medizin Mannheim der Universität
Heidelberg
Wiesbadener Straße 7-11
68305 Mannheim
Phone: 0621/3832854
Fax: 0621/3833833
Email: hochhaus@uni-hd.de
